Merck KGaA Just Made Its Biggest Bet in a Decade. Here's What It Bought.
Merck KGaA is spending $11.3 billion on Bio-Techne, its biggest acquisition in over a decade. The deal says something important about where the real money in biotech is heading, and it's not where you'd expect.
The Quiet Giant Just Got Loud
Merck KGaA hasn't made a splash like this since 2015. That year, the German pharma conglomerate dropped $17 billion on Sigma-Aldrich, a deal so big it reshaped the life sciences tools industry overnight. Then, for the better part of a decade, Merck went quiet on the megadeal front, opting for smaller, surgical acquisitions instead.
Until now.
On Monday, Merck KGaA agreed to acquire Bio-Techne for $11.3 billion, paying $73 per share in cash. It's the company's largest deal in over a decade, and it sends a very clear message: the picks-and-shovels business of biotech is worth paying up for, even when the rest of the industry is tightening its belt.
What Exactly Is Bio-Techne?
If you're not familiar with Bio-Techne, think of it as one of biotech's essential supply stores. The company doesn't make the drugs; it makes the stuff that helps other companies discover and manufacture them. Reagents, protein analysis tools, diagnostic platforms, spatial biology instruments. Over 500,000 products in total, sold to researchers and biopharma customers around the world.
The company runs two main business segments. Protein Sciences covers biological reagents, proteomic tools, and workflows for protein analysis. Diagnostics and Spatial Biology handles precision diagnostics and spatial detection technologies. Together, they generated roughly $1.2 billion in revenue in fiscal 2025, supported by about 3,100 employees across 34 global locations.
Bio-Techne isn't flashy. It doesn't have a blockbuster cancer drug or a viral gene therapy in Phase 3. But it has something arguably more valuable: a sticky, recurring-revenue business that researchers depend on every single day. It's the equivalent of selling hammers and nails during a construction boom. You don't need to pick the winning builder.
The Price Tag (and Whether It's Worth It)
Merck is paying a 36% premium to Bio-Techne's one-month volume-weighted average trading price, with some reports pegging the premium at . Either way, it's a hefty check for a company whose top line has been, well, flat.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
24% to the prior closing price
Bio-Techne's most recent quarter showed revenue of $321.2 million, up 1% year over year. Full-year fiscal 2026 revenue was essentially unchanged, and adjusted earnings per share barely budged ($1.93 vs. $1.92 the prior year). The stock had climbed about 23% year-to-date in 2026, but much of that gain appears to have been fueled by deal speculation rather than accelerating growth.
So why pay a premium for a company that's treading water? Because Merck isn't buying Bio-Techne for what it is today. It's buying it for what the combined portfolio could become.
Merck's Bigger Playbook
To understand this deal, you have to understand Merck KGaA's life science division. (Quick note for American readers: this is Merck KGaA, the Darmstadt-based company, not Merck & Co. in New Jersey. Different companies, confusingly similar names.)
Merck KGaA built its life science business through two foundational acquisitions. The Millipore deal in 2010 gave it bioscience and bioprocess capabilities. The Sigma-Aldrich deal in 2015 was the "quantum leap," creating a platform with three business units covering research solutions, process solutions, and applied solutions.
After Sigma-Aldrich, the company shifted to bolt-on deals and organic growth. That worked for a while, but the competitive landscape kept evolving. Danaher and Thermo Fisher, the two biggest gorillas in life science tools, have been using their massive scale and cash flows to snap up adjacent capabilities and lock customers into integrated workflows.
Bio-Techne fills a gap. Its reagent catalog and protein platforms complement Merck's existing portfolio, and its diagnostics business opens new territory. Think of it like a restaurant chain that already has a great kitchen but just acquired the best spice company in the market. Same ingredients, much better dishes.
The Bigger Picture: Why Tools Companies Are Hot
This deal doesn't exist in a vacuum. The life sciences tools sector is in the middle of a selective consolidation wave, and the trend is only accelerating.
Total signed M&A deals in life sciences hit $240 billion in 2025 according to one industry estimate, with another pegging the figure at $220 billion through November alone. Both numbers blew past 2024 levels. The mix has skewed toward smaller, smarter transactions (bolt-ons, carve-outs, platform plays), but larger deals are making a comeback.
The logic is straightforward. As more drugs become biologics (complex medicines made from living cells), the infrastructure needed to develop and manufacture them becomes increasingly valuable. Bioprocessing equipment, research reagents, analytical instruments: these are the railroads of modern drug development. Owning them means collecting tolls on nearly every drug that gets made.
AI is adding a new layer to this thesis. Industry surveys from KPMG and EY both flag AI-enabled tools, diagnostics, and data analytics as major drivers of deal activity heading into 2026 and beyond. Companies that combine broad product catalogs with data and software capabilities are commanding the richest valuations.
Wall Street's Verdict: A Collective Shrug
Analyst reaction to the deal has been mixed-to-neutral, which in Wall Street speak means "we see what you're doing, but prove it."
On the Bio-Techne side, consensus has settled around Hold/Neutral, with most price targets hovering near the $73 deal price. There's not much upside left for shareholders beyond the deal closing. The stock was trading around $58.88 before the acquisition announcement, suggesting the market had largely priced in some deal speculation given the year-to-date gains.
For Merck KGaA, the conversation has shifted to execution risk. Analysts want to know if the acquisition can improve life science margins and boost earnings per share after integration. Some have revised estimates upward, but the cautious tone is unmistakable. Integrating an $11.3 billion deal is hard. Integrating it while maintaining margins is harder.
The deal still needs remaining regulatory approvals, with closing expected in late 2026 or early 2027. Bio-Techne shareholders already approved the transaction in September.
What This Means for the Rest of the Industry
If you're a mid-sized life science tools company right now, you're probably updating your investor deck. Merck KGaA just validated that research reagents, protein platforms, and bioprocessing assets command premium prices, even when revenue growth is flat.
Expect Danaher and Thermo Fisher to respond. Not necessarily with a counter-bid for Bio-Techne (that ship has sailed), but with deals of their own. The race to build end-to-end life science platforms is intensifying, and nobody wants to be the last one shopping in a market where valuations keep climbing.
For biotech startups and drug developers, the consolidation trend has a practical implication: fewer independent suppliers means more integrated (and potentially more expensive) workflow solutions. The tools you use to discover drugs are increasingly owned by the same small group of companies.
The picks-and-shovels play has always been the smartest bet in a gold rush. Merck KGaA just went all in on it.
4 min read
The Cancer That Disappeared in Every Single Patient
GSK's dostarlimab just won FDA approval for a specific type of rectal cancer after trial results that stunned the oncology world: a 100% clinical response rate in early cohorts. For eligible patients, it could mean beating cancer without chemo, radiation, or surgery.
